Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Plus Therapeutics, Inc.

Market Cap 27.39M 24.07M 22.18M 20.75M 38.93M 2.59B 39.61M 267M 103M 1.27B 103M 101M 4.43B P/E 2026 *
-1.01x
P/E 2027 * -1.66x
Enterprise Value 27.39M 24.07M 22.18M 20.75M 38.93M 2.59B 39.61M 267M 103M 1.27B 103M 101M 4.43B EV / Sales 2026 *
4.35x
EV / Sales 2027 * 1.43x
Free-Float
98.37%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plus Therapeutics, Inc.

1 day+2.51%
1 week-15.88%
Current month-29.90%
1 month-38.09%
3 months-34.17%
6 months-72.56%
Current year-68.14%
1 week 3.91
Extreme 3.91
4.57
1 month 3.91
Extreme 3.91
7.14
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
80.25
5 years 2.9
Extreme 2.9
1,050
10 years 2.9
Extreme 2.9
429,377.68
Manager TitleAgeSince
Chief Executive Officer 64 01/04/2014
Director of Finance/CFO 52 05/02/2020
Chief Tech/Sci/R&D Officer - 20/10/2025
Director TitleAgeSince
Director/Board Member 64 30/09/2002
Chairman 77 24/01/2018
Director/Board Member 66 31/12/2019
Date Insider Type Main position Quantity % Market Cap.
05-13Free

Director

7,372 0.1074%
05-13Free

Director

8,972 0.1307%
05-13Free

Director

7,372 0.1074%
Change 5-day change 1-year change 3-year change Capi.($)
+2.51%-15.88%-15.88%-94.54% 27.39M
+2.96%+4.08%-8.03%-2.24% 43.24B
+2.23%+5.90%+327.41%+578.85% 35.25B
+1.59%+2.96%+11.76%+48.53% 30.22B
+2.07%-3.99%+10.70%-19.82% 28.01B
-4.75%-8.29%+3.90%+13.88% 24.08B
+4.64%+6.85% - - 14.16B
+3.91%+1.28%+53.05%+110.81% 13.01B
+2.77%+2.93%+9.65%+11.90% 12.7B
+0.13%+2.74%+103.13%+84.44% 12.54B
Average +1.56%-2.50%+55.08%+81.31% 21.32B
Weighted average by Cap. +1.24%-0.73%+70.57%+121.58%

Financials

2026 *2027 *
Net sales 6.3M 5.53M 5.1M 4.77M 8.95M 596M 9.1M 61.26M 23.66M 293M 23.63M 23.12M 1.02B 19.14M 16.82M 15.5M 14.5M 27.2M 1.81B 27.68M 186M 71.94M 889M 71.85M 70.3M 3.09B
Net income -26.8M -23.55M -21.7M -20.3M -38.09M -2.54B -38.75M -261M -101M -1.25B -101M -98.43M -4.33B -18.45M -16.22M -14.94M -13.98M -26.23M -1.75B -26.69M -180M -69.36M -858M -69.28M -67.78M -2.98B
Net Debt - -
Logo Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Employees
28
Date Price Change Volume
23/06/26 US$4.080 +2.51% 152,034
22/06/26 US$3.980 -5.24% 393,036
18/06/26 US$4.200 -2.55% 214,522
17/06/26 US$4.310 -5.69% 177,794
16/06/26 US$4.570 -5.77% 240,228
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.080USD
Average target price
36.00USD
Spread / Average Target
+782.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSTV Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!